Ivabradine, the selective inhibitor of the If current in the sinoatrial node, exerts cardiovascular protection by its bradycardic effect and potentially pleiotropic actions. However, there is a shortage of data regarding ivabradine's interaction with the renin-angiotensin-aldosterone system (RAAS). This study investigated whether ivabradine is able to protect a hypertensive heart in the model of L-NAME-induced hypertension and to interfere with the RAAS. Four groups (n = 10/group) of adult male Wistar rats were treated as follows for four weeks: control, ivabradine (10 mg/kg/day), L-NAME (40 mg/kg/day), and L-NAME plus ivabradine. L-NAME administration increased systolic blood pressure (SBP) and left ventricular (LV) weight, enhanced hydroxyproline concentration in the LV, and deteriorated the systolic and diastolic LV function. Ivabradine reduced heart rate (HR) and SBP, and improved the LV function. The serum concentrations of angiotensin Ang 1⁻8 (Ang II), Ang 1⁻5, Ang 1⁻7, Ang 1⁻10, Ang 2⁻8, and Ang 3⁻8 were decreased in the L-NAME group and ivabradine did not modify them. The serum concentration of aldosterone and the aldosterone/Ang II ratio were enhanced by L-NAME and ivabradine reduced these changes. We conclude that ivabradine improved the LV function of the hypertensive heart in L-NAME-induced hypertension. The protective effect of ivabradine might have been associated with the reduction of the aldosterone level.

3rd Department of Internal Medicine Faculty of Medicine Comenius University 83305 Bratislava Slovakia

Attoquant Diagnostics 1030 Vienna Austria

Department of Physiology School of Medicine Charles University 50003 Hradec Kralove Czech Republic

Institute of Experimental Endocrinology Biomedical Research Center Slovak Academy of Sciences 84505 Bratislava Slovakia

Institute of Normal and Pathological Physiology Center for Experimental Medicine Slovak Academy of Sciences 81371 Bratislava Slovakia

Institute of Pathophysiology Faculty of Medicine Comenius University Sasinkova 4 81108 Bratislava Slovakia

See more in PubMed

Silva F.C., Paiva F.A., Müller-Ribeiro F.C., Caldeira H.M., Fontes M., de Menezes R.C., Casali K.R., Fortes G.H., Tobaldini E., Solbiati M., et al. Chronic Treatment with Ivabradine Does Not Affect Cardiovascular Autonomic Control in Rats. Front. Physiol. 2016;7:305. doi: 10.3389/fphys.2016.00305. PubMed DOI PMC

Swedberg K., Komajda M., Böhm M., Borer J.S., Ford I., Dubost-Brama A., Lerebours G., Tavazzi L. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet. 2010;376:875–885. doi: 10.1016/S0140-6736(10)61198-1. PubMed DOI

Kleinbongard P., Gedik N., Witting P., Freedman B., Klöcker N., Heusch G. Pleiotropic, heart rate-independent cardioprotection by ivabradine. Br. J. Pharmacol. 2015;172:4380–4390. doi: 10.1111/bph.13220. PubMed DOI PMC

Walcher T., Bernhardt P., Vasic D., Bach H., Durst R., Rottbauer W., Walcher D. Ivabradine reduces chemokine-induced CD4-positive lymphocyte migration. Mediat. Inflamm. 2010;2010:751313. doi: 10.1155/2010/751313. PubMed DOI PMC

Custodis F., Baumhäkel M., Schlimmer N., List F., Gensch C., Böhm M., Laufs U. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2008;117:2377–2387. doi: 10.1161/CIRCULATIONAHA.107.746537. PubMed DOI

Dominguez-Rodriguez A., Fard S.S., Abreu-Gonzalez P., Bosa-Ojeda F., Consuegra-Sanchez L., Jiménez-Sosa A., Grande A.S., Kaski J.C. Randomised, double-blind, placebo-controlled trial of ivabradine in patients with acute coronary syndrome: Effects of the If current inhibitor ivabradine on reduction of inflammation markers in patients with acute coronary syndrome—RIVIERA trial study design and rationale. Cardiovasc. Drugs Ther. 2009;23:243–247. PubMed

Kröller-Schön S., Schulz E., Wenzel P., Kleschyov A.L., Hortmann M., Torzewski M., Oelze M., Renné T., Daiber A., Münzel T. Differential effects of heart rate reduction with ivabradine in two models of endothelial dysfunction and oxidative stress. Basic Res. Cardiol. 2011;106:1147–1158. doi: 10.1007/s00395-011-0227-3. PubMed DOI

Becher P.M., Lindner D., Miteva K., Savvatis K., Zietsch C., Schmack B., Van Linthout S., Westermann D., Schultheiss H.P., Tschöpe C. Role of heart rate reduction in the prevention of experimental heart failure: Comparison between If-channel blockade and β-receptor blockade. Hypertension. 2012;59:949–957. doi: 10.1161/HYPERTENSIONAHA.111.183913. PubMed DOI

Albaladejo P., Carusi A., Apartian A., Lacolley P., Safar M.E., Benetos A. Effect of chronic heart rate reduction with ivabradine on carotid and aortic structure and function in normotensive and hypertensive rats. J. Vasc. Res. 2003;40:320–328. doi: 10.1159/000072696. PubMed DOI

Pechanova O., Bernatova I., Pelouch V., Simko F. Protein remodelling of the heart in NO-deficient hypertension: The effect of captopril. J. Mol. Cell. Cardiol. 1997;29:3365–3374. doi: 10.1006/jmcc.1997.0566. PubMed DOI

Bernatova I., Pechanova O., Simko F. Effect of captopril in L-NAME-induced hypertension on the rat myocardium, aorta, brain and kidney. Exp. Physiol. 1999;84:1095–1105. doi: 10.1111/j.1469-445X.1999.01890.x. PubMed DOI

Simko F., Matuskova J., Luptak I., Krajcirovicova K., Kucharska J., Gvozdjakova A., Babal P., Pechanova O. Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension. Life Sci. 2004;74:1211–1224. doi: 10.1016/j.lfs.2003.07.032. PubMed DOI

Simko F., Matuskova J., Luptak I., Pincikova T., Krajcirovicova K., Stvrtina S., Pomsar J., Pelouch V., Paulis L., Pechánová O. Spironolactone differently influences remodeling of the left ventricle and aorta in L-NAME-induced hypertension. Physiol. Res. 2007;56:S25–S32. PubMed

Bernatova I., Pechanova O., Pelouch V., Simko F. Regression of chronic L-NAME-treatment-induced left ventricular hypertrophy: Effect of captopril. J. Mol. Cell. Cardiol. 2000;32:177–185. doi: 10.1006/jmcc.1999.1071. PubMed DOI

Simko F., Pechanova O., Pelouch V., Krajcirovicova K., Mullerova M., Bednarova K., Adamcova M., Paulis L. Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats. J. Hypertens. Suppl. 2009;27:S5–S10. doi: 10.1097/01.hjh.0000358830.95439.e8. PubMed DOI

Simko F., Pechanova O., Repova K., Aziriova S., Krajcirovicova K., Celec P., Tothova L., Vrankova S., Balazova L., Zorad S., et al. Lactacystin-induced model of hypertension in rats: Effects of melatonin and captopril. Int. J. Mol. Sci. 2017;18:1612. doi: 10.3390/ijms18081612. PubMed DOI PMC

Hegedusova N., Ondicova K., Mikova L., Horvathova L., Tillinger A., Mravec B. The effect of ivabradine administration on heart rate, blood pressure, and secretion of epinephrine, norepinephrine, and corticosterone during stress response in rats. Cardiol. Lett. 2014;23:403–409.

Luong L., Duckles H., Schenkel T., Mahmoud M., Tremoleda J.L., Wylezinska-Arridge M., Ali M., Bowden N.P., Villa-Uriol M.C., van der Heiden K., et al. Heart rate reduction with ivabradine promotes shear stress-dependent anti-inflamatory mechanisms in arteries. Thromb. Haemost. 2016;116:181–190. PubMed

Simko F., Simko J. The potential role of nitric oxide in the hypertrophic growth of the left ventricle. Physiol. Res. 2000;49:37–46. PubMed

Koniari I., Mavrilas D., Apostolakis E., Papadimitriou E., Papadaki H., Papalois A., Poimenidi E., Xanthopoulou I., Hahalis G., Alexopoulos D. Inhibition of Atherosclerosis Progression, Intimal Hyperplasia, and Oxidative Stress by Simvastatin and Ivabradine May Reduce Thoracic Aorta’s Stiffness in Hypercholesterolemic Rabbits. J. Cardiovasc. Pharmacol. Ther. 2016;21:412–422. doi: 10.1177/1074248415617289. PubMed DOI

Custodis F., Fries P., Müller A., Stamm C., Grube M., Kroemer H.K., Böhm M., Laufs U. Heart rate reduction by ivabradine improves aortic compliance in apolipoprotein E-deficient mice. J. Vasc. Res. 2012;49:432–440. doi: 10.1159/000339547. PubMed DOI

Dedkov E.I., Zheng W., Christensen L.P., Weiss R.M., Mahlberg-Gaudin F., Tomanek R.J. Preservation of coronary reserve by ivabradine-induced reduction in heart rate in infarcted rats is associated with decrease in perivascular collagen. Am. J. Physiol. Heart Circ. Physiol. 2007;293:H590–H598. doi: 10.1152/ajpheart.00047.2007. PubMed DOI

Busseuil D., Shi Y., Mecteau M., Brand G., Gillis M.A., Thorin E., Asselin C., Roméo P., Leung T.K., Latour J.G., et al. Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis. Cardiology. 2010;117:234–242. doi: 10.1159/000322905. PubMed DOI

Rienzo M., Melka J., Bizé A., Sambin L., Jozwiak M., Su J.B., Hittinger L., Berdeaux A., Ghaleh B. Ivabradine improves left ventricular function during chronic hypertension in conscious pigs. Hypertension. 2015;65:122–129. doi: 10.1161/HYPERTENSIONAHA.114.04323. PubMed DOI

Kim B.H., Cho K.I., Kim S.M., Kim N., Han J., Kim J.Y., Kim I.J. Heart rate reduction with ivabradine prevents thyroid hormone-induced cardiac remodeling in rat. Heart Vessels. 2013;28:524–535. doi: 10.1007/s00380-012-0304-z. PubMed DOI

Ciobotaru V., Heimburger M., Louedec L., Heymes C., Ventura-Clapier R., Bedossa P., Escoubet B., Michel J.B., Mercadier J.J., Logeart D. Effect of long-term heart rate reduction by If current inhibition on pressure overload-induced heart failure in rats. J. Pharmacol. Exp. Ther. 2008;324:43–49. doi: 10.1124/jpet.107.130237. PubMed DOI

Oliphant C.S., Owens R.E., Bolorunduro O.B., Jha S.K. Ivabradine: A Review of Labeled and off-Label Uses. Am. J. Cardiovasc. Drugs. 2016;16:337–347. doi: 10.1007/s40256-016-0178-z. PubMed DOI

Dias da Silva V.J., Tobaldini E., Rocchetti M., Wu M.A., Malfatto G., Montano N., Zaza A. Modulation of sympathetic activity and heart rate variability by ivabradine. Cardiovasc. Res. 2015;108:31–38. doi: 10.1093/cvr/cvv180. PubMed DOI

Simko F., Baka T., Krajcirovicova K., Repova K., Aziriova S., Zorad S., Poglitsch M., Adamcova M., Reiter R.J., Paulis L. Effect of Melatonin on the Renin-Angiotensin-Aldosterone System in l-NAME-Induced Hypertension. Molecules. 2018;23:265. doi: 10.3390/molecules23020265. PubMed DOI PMC

Muldowney J.A., Davis S.N., Vaughan D.E., Brown N.J. NO synthase inhibition increases aldosterone in humans. Hypertension. 2004;44:739–745. doi: 10.1161/01.HYP.0000143852.48258.f1. PubMed DOI

Suehiro T., Tsuruya K., Ikeda H., Toyonaga J., Yamada S., Noguchi H., Tokumoto M., Kitazono T. Systemic Aldosterone, But Not Angiotensin II, Plays a Pivotal Role in the Pathogenesis of Renal Injury in Chronic Nitric Oxide-Deficient Male Rats. Endocrinology. 2015;156:2657–2666. doi: 10.1210/en.2014-1369. PubMed DOI

Funder J.W. Aldosterone and mineralocorticoid receptors-physiology and pathophysiology. Int. J. Mol. Sci. 2017;18:1032. doi: 10.3390/ijms18051032. PubMed DOI PMC

Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999;341:709–717. doi: 10.1056/NEJM199909023411001. PubMed DOI

Zile M.R., Brutsaert D.L. New concepts in diastolic dysfunction and diastolic heart failure: Part II: Causal mechanisms and treatment. Circulation. 2002;105:1503–1508. doi: 10.1161/hc1202.105290. PubMed DOI

Jeong E.M., Monasky M.M., Gu L., Taglieri D.M., Patel B.G., Liu H., Wang Q., Greener I., Dudley S.C., Jr., Solaro R.J. Tetrahydrobiopterin improves diastolic dysfunction by reversing changes in myofilament properties. J. Mol. Cell. Cardiol. 2013;56:44–54. doi: 10.1016/j.yjmcc.2012.12.003. PubMed DOI PMC

Silberman G.A., Fan T.H., Liu H., Jiao Z., Xiao H.D., Lovelock J.D., Boulden B.M., Widder J., Fredd S., Bernstein K.E., et al. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation. 2010;121:519–528. doi: 10.1161/CIRCULATIONAHA.109.883777. PubMed DOI PMC

Shahbaz A.U., Kamalov G., Zhao W., Zhao T., Johnson P.L., Sun Y., Bhattacharya S.K., Ahokas R.A., Gerling I.C., Weber K.T. Mitochondria-targeted cardioprotection in aldosteronism. J. Cardiovasc. Pharmacol. 2011;57:37–43. doi: 10.1097/FJC.0b013e3181fe1250. PubMed DOI PMC

Matsumoto T., Oki K., Kajikawa M., Nakashima A., Maruhashi T., Iwamoto Y., Iwamoto A., Oda N., Hidaka T., Kihara Y., et al. Effect of aldosterone-producing adenoma on endothelial function and Rho-associated kinase activity in patients with primary aldosteronism. Hypertension. 2015;65:841–848. doi: 10.1161/HYPERTENSIONAHA.114.05001. PubMed DOI PMC

Paulis L., Rajkovicova R., Simko F. New developments in the pharmacological treatment of hypertension: Dead-end or a glimmer at the horizon? Curr. Hypertens. Rep. 2015;17:557. doi: 10.1007/s11906-015-0557-x. PubMed DOI PMC

Mulrow P.J. Angiotensin II and aldosterone regulation. Regul. Pept. 1999;80:27–32. doi: 10.1016/S0167-0115(99)00004-X. PubMed DOI

Rebuffat P., Malendowicz L.K., Nussdorfer G.G., Mazzocchi G. Stimulation of endogenous nitric oxide production is involved in the inhibitory effect of adrenomedullin on aldosterone secretion in the rat. Peptides. 2001;22:923–926. doi: 10.1016/S0196-9781(01)00418-1. PubMed DOI

Nithipatikom K., Holmes B.B., McCoy M.J., Hillard C.J., Campbell W.B. Chronic administration of nitric oxide reduces angiotensin II receptor type 1 expression and aldosterone synthesis in Zona glomerulosa cells. Am. J. Physiol. Endocrinol. Metab. 2004;287:E820–E827. doi: 10.1152/ajpendo.00183.2004. PubMed DOI

Pelouch V., Milerova M., Ostadal B., Samanek M., Hucin B. Protein profiling of human atrial and ventricular musculature: The effect of normoxaemia and hypoxaemia in congenital heart diseases. Physiol. Res. 1993;42:235–242. PubMed

Reddy G.K., Enwemeka C.S. A simplified method for the analysis of hydroxyproline in biological tissues. Clin. Biochem. 1996;29:225–229. doi: 10.1016/0009-9120(96)00003-6. PubMed DOI

Basu R., Poglitsch M., Yogasundaram H., Thomas J., Rowe B.H., Oudit G.Y. Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure. J. Am. Coll. Cardiol. 2017;69:805–819. doi: 10.1016/j.jacc.2016.11.064. PubMed DOI

Domenig O., Manzel A., Grobe N., Königshausen E., Kaltenecker C.C., Kovarik J.J., Stegbauer J., Gurley S.B., van Oyen D., Antlanger M., et al. Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney. Sci. Rep. 2016;6:33678. doi: 10.1038/srep33678. PubMed DOI PMC

Pavo N., Goliasch G., Wurm R., Novak J., Strunk G., Gyöngyösi M., Poglitsch M., Säemann M.D., Hülsmann M. Low- and High-renin Heart Failure Phenotypes with Clinical Implications. Clin. Chem. 2018;64:597–608. doi: 10.1373/clinchem.2017.278705. PubMed DOI

Baka T., Hodosy J., Krajcirovicova K., Repova K., Aziriova S., Domonkos E., Borbelyova V., Slavkovsky P., Zorad S., Celec P., et al. 17β-Estradiol treatment reversed left ventricular dysfunction in castrated male rats: An echocardiographic study. Can. J. Physiol. Pharmacol. 2018;96:850–854. doi: 10.1139/cjpp-2017-0596. PubMed DOI

Liu J., Rigel D.F. Echocardiographic examination in rats and mice. Methods Mol. Biol. 2009;573:139–155. PubMed

Sacubitril/Valsartan Alleviates Cardiac Remodeling and Dysfunction in L-NAME-Induced Hypertension and Hypertensive Heart Disease

Sacubitril/Valsartan and Ivabradine Attenuate Left Ventricular Remodelling and Dysfunction in Spontaneously Hypertensive Rats: Different Interactions with the Renin-Angiotensin-Aldosterone System

Ivabradine improves survival and attenuates cardiac remodeling in isoproterenol-induced myocardial injury

The Impact of microRNAs in Renin-Angiotensin-System-Induced Cardiac Remodelling

Renin-Angiotensin-Aldosterone System: Friend or Foe-The Matter of Balance. Insight on History, Therapeutic Implications and COVID-19 Interactions

Ivabradine Ameliorates Kidney Fibrosis in L-NAME-Induced Hypertension